GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Abattis Bioceuticals Corp (OTCPK:ATTBF) » Definitions » Current Ratio

Abattis Bioceuticals (Abattis Bioceuticals) Current Ratio : 0.73 (As of Sep. 2019)


View and export this data going back to . Start your Free Trial

What is Abattis Bioceuticals Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Abattis Bioceuticals's current ratio for the quarter that ended in Sep. 2019 was 0.73.

Abattis Bioceuticals has a current ratio of 0.73. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Abattis Bioceuticals has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for Abattis Bioceuticals's Current Ratio or its related term are showing as below:

ATTBF's Current Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.85
* Ranked among companies with meaningful Current Ratio only.

Abattis Bioceuticals Current Ratio Historical Data

The historical data trend for Abattis Bioceuticals's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abattis Bioceuticals Current Ratio Chart

Abattis Bioceuticals Annual Data
Trend Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.31 0.09 1.54 34.60 0.73

Abattis Bioceuticals Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.60 18.94 17.41 0.91 0.73

Competitive Comparison of Abattis Bioceuticals's Current Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Abattis Bioceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abattis Bioceuticals's Current Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Abattis Bioceuticals's Current Ratio distribution charts can be found below:

* The bar in red indicates where Abattis Bioceuticals's Current Ratio falls into.



Abattis Bioceuticals Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Abattis Bioceuticals's Current Ratio for the fiscal year that ended in Sep. 2019 is calculated as

Current Ratio (A: Sep. 2019 )=Total Current Assets (A: Sep. 2019 )/Total Current Liabilities (A: Sep. 2019 )
=2.72/3.71
=0.73

Abattis Bioceuticals's Current Ratio for the quarter that ended in Sep. 2019 is calculated as

Current Ratio (Q: Sep. 2019 )=Total Current Assets (Q: Sep. 2019 )/Total Current Liabilities (Q: Sep. 2019 )
=2.72/3.71
=0.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abattis Bioceuticals  (OTCPK:ATTBF) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Abattis Bioceuticals Current Ratio Related Terms

Thank you for viewing the detailed overview of Abattis Bioceuticals's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Abattis Bioceuticals (Abattis Bioceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1200 - 625 Howe Street, Vancouver, BC, CAN, V6C 2M6
Abattis Bioceuticals Corp is a Canadian life science and biotechnology company focuses on aggregating, integrating and investing in agricultural technologies and biotechnology services for the legal cannabis industry. It is primarily engaged in producing, licensing and marketing proprietary ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The company is also engaged in growing, extraction, testing, propagation and online distribution.

Abattis Bioceuticals (Abattis Bioceuticals) Headlines